ArticleBreast (Edinburgh, Scotland)2026
Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological complete response (pCR) after neoadjuvant therapy (NAT) is associated with long-term outcomes in breast cancer (BC). The remnant cholesterol inflammatory index (RCII) integrates lipid-related and inflammatory components, but its role in pCR prediction remains unclear.
methodsThis multicenter retrospective study included women with invasive BC treated with NAT between January 2022 and January 2026. Prespecified multivariable logistic regression models incorporating baseline inflammatory, metabolic, and clinicopathologic variables were developed in a training cohort and evaluated in an independent external validation cohort without recalibration. Model performance was assessed using discrimination and calibration metrics.
resultsAmong 422 patients, 157 (37.2%) achieved pCR. In the clinically adjusted model, triple-negative BC (OR 7.56, 95% CI 2.74-20.86), HER2-positive BC (OR 4.13, 95% CI 2.15-7.92), and lower log-RCII (OR 0.48, 95% CI 0.33-0.69) were independently associated with pCR. External validation yielded an AUC of 0.84 (95% CI 0.76-0.91). The calibration slope was 0.94, while the calibration intercept of -0.60 indicated systematic overprediction of pCR probability. Sensitivity and internal validation analyses supported the robustness of the primary findings.
conclusionLog-RCII was independently associated with pCR and provided incremental predictive information beyond standard clinicopathologic factors. The model showed favorable discrimination in the external validation cohort, but systematic overprediction indicates that further prospective validation and potential recalibration are warranted before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.